Introduction {#s1}
============

Epilepsy is a progressive chronic disorder characterized by an abnormal and synchronous neuronal firing associated with recurrent and unpredictable seizures ([@B12]). It affects more than 50 million people worldwide. The current antiepileptic drug arsenal fails to evoke a positive response in about 30% of diagnosed cases of epilepsy ([@B37]). Patients suffering from different types of epilepsy are often affected by psychiatric and behavioral comorbidities such as mood disorders, anxiety, psychoses, motor disorders, cognitive deficits, and social dysfunctions ([@B35]). Besides the broad epidemiological relevance of anxiety disorders at different segments of our modern society, anxiety disorders are usually observed in a large number of epileptic patients, which represents additional negative impacts in their already compromised quality of lives ([@B15]). It is well known that the alleviation of anxiety symptoms may have a positive effect in the progress of treatment of epileptic patients contributing to ameliorate their general health condition ([@B13]).

The pathophysiological mechanism related to the onset and maintenance of different types of epilepsy/seizures, includes the imbalance between excitatory (glutamate) and inhibitory (γ-aminobutyric acid (GABA) synaptic activities that are located at different brain areas ([@B6]). Some brain networks are commonly involved at prevention or appearance of seizures as well as in the regulation of behavior and mood ([@B23]). Although the huge differences in the molecular and cellular bases involved in onset and development of epilepsy and anxiety, the same imbalance between GABA and Glutamate is also related to anxiety ([@B26]; [@B16]). Of course, several intervenient factors can differentially contribute to the neuropathology underlying both disorders, particularly in terms of magnitude, recruited structures, and brain areas ([@B25]; [@B39]). In any case, the screening for new antiepileptic/anxiolytic drugs that are able to modulate the inhibitory and/or excitatory neurotransmission pathways may be worth for the treatment of epilepsy and/or anxiety ([@B28]).

Vitexin (apigenin-8-C-glucoside) has received great attention by presenting a wide range of pharmacological effects. Vitexin has been found, in some cases as the major constituent, at different medicinal plants potentially useful to treat anxiety and/or epilepsy ([@B29]; [@B21]). More specifically, recent studies have shown the protective effects of vitexin against some neurological and psychiatric diseases ([@B2]; [@B7]; [@B17]). In spite of the interesting pharmacological properties of vitexin; only a few and preliminary efforts have been conducted to prove its potential anxiolytic and anticonvulsant activities. Therefore, the main aim of this work is to investigate these potential effects using a complementary set of experiments at a well-established animal model arrangement.

Materials and Methods {#s2}
=====================

Vitexin and Other Drugs {#s2_1}
-----------------------

Vitexin (apigenin-8-C-glucoside) was purchased from Cayman Chemical Company, USA (CAS Number 3681-93-4, purity degree ≥ 98%). The proconvulsant drugs N-Methyl-D-aspartate (NMDA) (CAS Number: 6384-92-5; ≥ 98%); kainic acid (CAS Number: 58002-62-3; ≥ 98%); Pentylenetetrazol (PTZ) (CAS Number: 54-95-5) and picrotoxin (CAS Number 204-716-6) were purchased from Sigma Aldrich, St. Louis, MO. Diazepam (DZP) (injectable solution in 0.9% saline) and dimethyl sulfoxyde (DMSO) were acquired from União Química (Brazil) and Synth (Brazil), respectively.

Animals and Experimental Conditions {#s2_2}
-----------------------------------

All experiments were carried out using male adult Wistar rats within 4 to 5 weeks of age weighing about 150 to 180 g. Rats were housed five per cage in a controlled condition of humidity and temperature under 12 h light/dark schedule at 6 am/6 pm. They were allowed to acclimatize to our host facilities for at least 3 days prior to any experimental manipulation. Chow and water were provided *ad libitum*. The procedures were in accordance with the University of Ribeirão Preto Ethic Committee (approval number 11/2015) and with the Guide for the Care and Use of Laboratory Animals (National Research Council, US).

The animals were divided in control and experimental groups (*n*=06) in all sets of experiments. All the experiments were carried out in an acoustic isolated room between 1:00 to 5:00 p.m. All apparatus or arenas used in experiments were cleaned with 70% ethanol after observation of each animal in all of the procedures. Rats were habituated to the testing room for 30-min before experimental procedures. All experiments were recorded by a digital video camera and copies of files kept in our laboratory as official documents for public consultation.

Assessment of Anxiolytic-Like Effects of Vitexin {#s3}
================================================

The anxiolytic activity of vitexin was evaluated by elevated plus-maze, light-dark box, and open-field tests. The behavior of animals on each experimental apparatus for anxiolytic effects was observed 30 min later after control or experimental treatments. For all experiments, Diazepam 2 mg/kg (dissolved in 0.9% saline) (i.p.) served as positive control while 1% DMSO in 0.9% saline (i.p.) and 0.9% saline solution (i.p.) served as controls. Experimental groups were composed of animals treated with different i.p. doses of vitexin (0.75, 1.25 and 2.5 mg/kg). Doses of vitexin were selected based on pilot scale tests while the dose of DZP were based on previous scientific reports ([@B22]; [@B41])

Elevated Plus-Maze Test {#s3_1}
-----------------------

The elevated plus maze (EPM) was conducted in accordance with the method validated by [@B32].The maze comprised of two wood open arms (50 × 10 cm) surrounded by a short (0.5 cm) acrylic edge to avoid falls and two wood enclosed arms (50 × 10 × 40 cm) arranged such that the two open arms were opposite to each other. The arms were connected by a central platform (10 × 10 cm) and the maze was kept 50 cm above the floor. Each rat was placed in the middle compartment (head facing an open arm) and allowed to freely explore the apparatus for 5 min. It was measured (i) the time spent(s) in the open and closed arms of the EPM, (ii) the percentage of time spent in open arms, (iii) protected and unprotected stretch attend postures, and (iv) protected and unprotected head dipping events. Stretch-attend was defined when the animal stretches forward and retracts without moving its feet. Head dipping was defined as the exploratory movement in which the rodent head protruding over the edge toward the floor on the open arms. Behaviors were defined unprotected when they were exhibited in the open arm region of the EPM and were protected if it occurs in closed arms or central platform of the maze ([@B36]).

Open Field Test {#s3_2}
---------------

The open field test was performed according to the method previously described ([@B14]).The open-field used was a circular arena measuring 60 cm in diameter with 50-cm high circular acrylic wall (OP0199, Insight). The apparatus floor was divided into 12 squares (4 squares corresponding a central zone and 8 squares to the peripheral zones).Every animal was placed in the central region of the open field, and the number of lines crossed (all four limbs), rearing, grooming, and the times spent(s) in the central zone of the apparatus were recorded for 5 minutes. Also, for an indirect measurement of locomotor performance of animals, the number of crossings was checked in time blocks along the experiment comparing control and experimental groups, since the animals usually explore more of the apparatus in the first blocks of time and less at the end of the task, as they habituate.

Light-Dark Box Test {#s3_3}
-------------------

The light-dark box consist of a *box* (46 x 27 x 30 cm) divided into a dark and illuminated compartment (EP 158, Insight, fluorescent lamp- 20 W). The chambers were connected by a small opening (7.5 × 7.5 cm) in the middle of the wall separating the two chambers. Rats were placed in the middle of the light chamber and then released to explore for 5 min ([@B20]).The time that rats spent in the light/dark compartments and the number of transitions between them were recorded. Transition was defined as the placement of all four paws in the entry chamber.

Assessment of Anticonvulsant Activity of Vitexin {#s4}
================================================

The anticonvulsant effect of vitexin was evaluated against chemically-induced seizures by *intraperitoneal (i.p.) injection* of proconvulsant agents: NMDA, 150 mg/kg; kainic acid, 30 mg/kg; picrotoxin, 6 mg/kg; and PTZ 90, mg/kg. NMDA, kainic acid, picrotoxin, and PTZ were dissolved in 0.9% saline while vitexin dissolved in 0.9% saline containing dimethyl sulfoxyde -- DMSO 1%. The animals control and experimental groups were divided according to the assessment of anxiolytic-like effects of vitexin, except by the range of vitexin i.p. doses, which were slightly up changed for anticonvulsant screening (1.25, 2.5, and 5 mg/kg). Doses of vitexin were selected based on pilot scale tests while the dose of DZP were selected based on previous scientific reports, as considered above for anxiolytic-related tests. Thirty minutes after the administration of each proconvulsant drug, each animal was maintained individually in a transparent *acrylic arena* (60 cm × 40 cm). The rats were observed for 30, 40, 40, and 120 min respectively for kainic acid, NMDA, picrotoxin, and PTZ assays. It was evaluated the latency time to the first generalized tonic-clonic seizure and the incidence/number of animals exhibiting generalized tonic-clonic seizures ([@B14]). Animal behavior seizure rating was classified/certified according to the Racine's scale, modified by Pinel and Rovner ([@B33]). Generalized tonic-clonic seizures were considered as those rating score 7 or more in accordance to this scale and analyses of our video-recorded files.

Statistical Analysis {#s4_1}
--------------------

Except by the Open-Field test which was performed one and two-way ANOVA test, other experiments statistical analyses were performed using One-way ANOVA, followed by the Tukey post-hoc test (GraphPad Prism; version 7.0, Graphpad Software, USA). Data were expressed as the means ± standard error of mean (SEM) (*n*=06/group). A level of p\< 0.05 was accepted as statistically significant.

Results {#s5}
=======

Anxiolytic-Like Effects of Vitexin {#s5_1}
----------------------------------

### Elevated Plus-Maze {#s5_1_1}

The amount of time (sec) spent in the open and closed arms and percentage of time spent in open arms in the elevated plus maze are shown in [**Figure 1**](#f1){ref-type="fig"}. The *post hoc* test showed that the time spent on the open arms was longer (*p* \< 0.05) in the diazepam treated group (positive control). Also, the data shows that all doses of vitexin increased significantly the time spent in the open arms compared to the saline control (F~(5,60)~ = 103.9; p\<0.05). Pretreatment with vitexin produced a significant increase in unprotected head dipping (F~(5,30)~ = 74.25; p\<0.05) and unprotected stretch-attend postures (F~(5,30)~ = 27.99; p\<0.05).

![Elevated Plus Maze. **(A)** Total time spent on the open and closed arms, **(B)** percentage of time spent in opens arms, **(C)** protected and unprotected stretch attend postures and **(D)** protected and unprotected head dipping between the groups treated with different doses of vitexin, diazepam (DZP), and vehicle (VEH), compared with control group (Ctrl - Saline Control). Significantly different from saline control group: ^∗^*p* \< 0.05. One-way ANOVA; Tukey *post hoc* test.](fphar-11-01181-g001){#f1}

### Open Field Test {#s5_1_2}

The number of line crossings during open field test showed that vitexin increased locomotion on apparatus (F~(5,26)~ = 45.33; p\<0.05) ([**Figure 2A**](#f2){ref-type="fig"}). Vitexin significantly improved locomotion mainly in the first 3 minutes of experimentation when compared with the control group (F ~(20,\ 140)~ = 26,23 p\<0.05) ([**Figure 2B**](#f2){ref-type="fig"}). In the open field test, animals treated with vitexin (all doses) spent more time on the center of arena when compared with those from the control group (F~(5,30)~ = 76.82; p\<0.05) ([**Figure 2C**](#f2){ref-type="fig"}). Vertical activity behaviors (rearing and grooming) are shown in [**Figure 2D**](#f2){ref-type="fig"}. The analysis of total number of the rearing showed significantly higher for vitexin treatments than that in the control group (saline) (F~(5,27)~ = 67.49; p\<0.05). The *post hoc* test revealed that vitexin 0.75 and 1.25 mg/kg reduced grooming behaviors (compared with the control group) in a way similar to the diazepam (F~(5,27)~ = 40.02; p\<0.05) ([**Figure 2D**](#f2){ref-type="fig"}).

![Open Field Test. **(A)** number of crossings made in the open field, **(B)** Crossings in function of the time, **(C)** time spent in the center and **(D)** rearing and grooming behavior of the open field by different doses of vitexin, diazepam (DZP), and vehicle (VEH), compared with control group (Ctrl---saline control). Significantly different from saline control: ^∗^*p* \< 0.05. For data in **(A, C** and **D)** was performed one-way ANOVA and in **(B)** was performed two-way ANOVA. For all data were performed Tukey *post hoc* test.](fphar-11-01181-g002){#f2}

### Light-Dark Test {#s5_1_3}

Vitexin at the dose of 0.75, 1.25, and 2.5 mg/kg and diazepam (2 mg/kg) induced a significant increase in the time spent by rats on the illuminated side of the apparatus compared with the saline control group (F~(5;50)~ = 26.87; p\<0.05) ([**Figure 3A**](#f3){ref-type="fig"}). Analysis of the light/dark transitions revealed significant greater number of transitions for animals treated with vitexin than in the control group (F~(5,28)~ = 21.33; p\<0.05) ([**Figure 3B**](#f3){ref-type="fig"}).

![Light dark box test. **(A)** times spent(s) on light/dark area and **(B)** light/dark transitions by different doses of vitexin, diazepam (DZP) and vehicle (VEH) compared with control group (Ctrl---saline control). Significantly different from saline control: ^∗^*p* \< 0.05. One-way ANOVA; Tukey *post hoc* test.](fphar-11-01181-g003){#f3}

Anticonvulsant Screening {#s5_2}
------------------------

Acute administration of vitexin prior to kainic acid and NMDA injections did not protect animals against seizures. However, clonic seizures induced by i.p. administrations of PTZ and picrotoxin were inhibited by all doses of vitexin ([**Figures 4A, B**](#f4){ref-type="fig"}). Vitexin significantly protected animals against seizures and showed 16.66, 50 and 100% of protection against picrotoxin-induced seizures ([**Figure 4C**](#f4){ref-type="fig"}) and 16.66%, 33.33%, and 100% against PTZ-induced seizures ([**Figure 4D**](#f4){ref-type="fig"}), respectively, on the doses of 1.25; 2.5, and 5 mg/kg. Therefore, the anticonvulsant activity of vitexin exhibited a dose-dependent profile on PTZ and picrotoxin assays. In addition, the latency to to the first seizure induced by PTZ and picrotoxin was significantly higher for groups treated with vitexin, particularly on the dose of 2.5 mg/kg ([**Table 1**](#T1){ref-type="table"}).

![Percentages of animals protected against seizures induced by **(A)** kainic acid 150 mg/kg, **(B)** NMDA 150 mg/kg, **(C)** picrotoxin 6 mg/kg and **(D)** PTZ 90 mg/kg in function of different doses of vitexin, diazepam (DZP), and vehicle (VEH) compared with control group (Ctrl-Saline Control). Significantly different from control: \**p* \< 0.05 versus saline control group. One-way ANOVA; Tukey *post hoc* test.](fphar-11-01181-g004){#f4}

###### 

Latency to onset of seizure (score 7-8) on vitexin treatments.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Convulsant Agent         Latency* *to* *onset of seizure (seconds)                                                                       
  ------------------------ ------------------------------------------- ----------------- ---- --------------------- ---------------------- ------------------
  NMDA (150 mg/kg)         4409.50 ± 92.48                             4326.30 ± 43.49   NS   4403.83 ± 98.63       4514.50 ± 63.59        4548.50 ± 70.52

  Kainic acid (30 mg/kg)   4491.33 ± 77.88                             4546.33 ± 77.52   NS   4693.0 ± 74.59        4404.83 ± 116.83       4468.72 ± 124.72

  PTZ\                     77.4 ± 14.63                                78.00 ± 7.38      NS   53.66 ± 9.07^\#^      141.2 ± 29.08\*^\#^    \*^\#^\
  (90 mg/kg)                                                                                                                               NS

  Picrotoxin (6 mg/kg)     1101.0 ± 47.29                              1103.66 ± 47.99   NS   745.8 ± 65.35\*^\#^   1396.6 ± 43.14\*^\#^   \*^\#^\
                                                                                                                                           NS
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

∗p \< 0.05 versus control group (Ctrl -- Saline Control) and ^\#^p \< 0.05 between different doses of vitexin. One-way ANOVA; Tukey post hoc test. NS, no seizure.

Discussion {#s6}
==========

In the present study we demonstrated that vitexin presents both anxiolytic and anticonvulsant properties which are possibly mediated by modulation of GABAergic neurotransmission and/or related synaptic pathways. Since those pharmacological activities were achieved after systemic administration (i.p.) of vitexin, it is plausible to affirm that this compound overcomes the blood-brain barrier, making it more attractive in terms of pharmacokinetic or even pharmaceutical perspectives. Vitexin has been found at different medicinal plants with anxiolytic and/or anti-epileptic properties ([@B29]; [@B27]). Based on this and also on our results, it is also possible to suggest that vitexin is at least partially responsible for those pharmacological activities, in most of cases and more probabilistically, acting in a synergistic way with other(s) active compound(s) present in those plants claimed as anxiolytics and/or anti-epileptics.

In the present study, anxiolytic-like effect of vitexin was confirmed by three different and complementary animal screening tests. This combined arrangement of tests allows a more reliable and complete evaluation of anxiety-related behaviors in rodents ([@B34]). Overall results from different tests confirmed the increase of exploratory performance and the decrease of aversive behaviors of animals, indicating an anxiolytic-like effect promoted by the different doses of vitexin. Anxiolytics agents reduce protected risk assessment behaviors and increase the frequency of unprotected ethological behaviors ([@B3]). Similar to diazepam, pretreatment with vitexin significantly decreased protected head dips and stretch attend postures and increase unprotected behavior suggesting the anxiolytic property of vitexin. In addition, it is possible to reinforce that vitexin did not caused any type of locomotor impairment or even did not produced signals of sedation on animals at same time that the anticonvulsant activity produced by vitexin is not caused by interference with locomotor capacity of the treated animals. Those conclusions are supported by the increased number of crossings at open field test and the increased number of light/dark transitions exhibited by vitexin treated animals in the light/dark box test when compared with the saline control. Locomotor impairment or severe sedation are constantly claimed as important side effects caused by different pharmacological agents used in the treatment of anxiety and epilepsy and should be avoided in the clinical management of those medical conditions ([@B8]; [@B18]). Therefore, besides the useful dual pharmacological effect (anxiolytic and anticonvulsant) vitexin presents some advantages in terms of its toxicological profile. The dual effect of vitexin at a very similar range of doses is particularly important for a potential combined and future management of both epilepsy and anxiety, which commonly appears as comorbidities and request the use of several combined drugs. However, this dual pharmacological effect is not surprising or exclusive of vitexin, since epilepsy and anxiety are partially overlapped in terms of neurochemical and neurobiological pathways and some drugs depending on the dose (like benzodiazepines) may act against both disorders despite important observed side effects.

The effect of acute intraperitoneal injection of the vitexin for the prospect of its anticonvulsant activity was evaluated using different acute seizure models in which the seizures were chemically induced. Given the possibility of false negatives results on drug screening, potential antiepileptic compounds should not be screened solely against one single model but to be tested across a few different seizure models, exploring at same time different neurotransmission pathways involved on initiation and spraying of induced seizures ([@B40]). These type of animal models are very useful for the rapid and economical screening of new anticonvulsant drugs ([@B24]). Kainic acid and NMDA have significant convulsant effects, fundamentally by activating glutamate receptors; glutamate is the most prominent excitatory neurotransmitter in the mammalian CNS ([@B5]). Moreover, in the current study, we explored the therapeutic potential of vitexin using the GABA~A~ receptor antagonists PTZ and picrotoxin ([@B9]). On the basis of the results presented here, acute treatment with different doses of vitexin applied against the kainic acid and NMDA seizures protocol was not effective when compared with the saline control. In contrast, vitexin exhibited a very clear dose-dependent anticonvulsant effect against seizures induced by PTZ and picrotoxin, reaching the maximum protection (100%) at higher dose of 5 mg/kg. In addition, the lower doses (1.25 and 2.5 mg/kg) delayed the onset of seizures for non-completely protected animals against seizures. The combination of these actions indicated an effective anticonvulsant effect of vitexin at least against PTZ and picrotoxin-induced seizures.

The underlying molecular mechanisms involved in the anticonvulsant or anxiolytic actions of vitexin were not the central scope of the present study. However, the selective protection offered by vitexin against GABA receptors antagonists at the expense of Glutamate receptor agonists are at least intriguing and may suggest that the modulation of GABA neurotransmission or related pathways may be involved on mode of action of vitexin. It is noteworthy to point out that different natural flavonoids and various synthetic derivatives from natural flavonoids are well known to be positive modulators of GABA~A~ receptors ([@B19]; [@B31]). Indeed, many studies agree that vitexin may exert its CNS effects *via* GABA~A~ receptor (benzodiazepine site) modulation ([@B1]; [@B30]; [@B38]). However, further neurochemical investigations are required for a more complete understanding by the way vitexin exerts its pharmacological activities. The GABA neurotransmission is a common link between epilepsy and anxiety. In fact, the down regulation of GABA activity is frequently evoked on the neurobiological explanation for both disorders. Also, the up modulation of GABAergic neurotransmission is assumed on the explanation about the mode of action of some drugs such as benzodiazepines, which are well known as a GABA~A~ receptors positive allosteric modulators and commonly used for the clinical management for both disorders ([@B4]).

Finally, epilepsy and anxiety frequently appear as comorbidities. Indeed, one of the main psychiatric conditions observed for epileptic patients is anxiety. Anxiety affects approximately 20% of the people diagnosed with epilepsy and is responsible for a decreased quality of life and can worsen epilepsy control ([@B11]; [@B38]). The actual pharmacological arsenal used in the clinical treatment for both disorders often causes important side effects, such as cognitive/locomotor impairments and sedation, which negatively affects therapeutic adherence ([@B10]). Thus, the prospecting/developing of new pharmacological probes is relevant especially when those new potential drugs exhibit potential advantages in terms of pharmacokinetics, toxicological, and pharmacodynamic features.

Conclusion {#s7}
==========

The results of this study showed that vitexin possess both anxiolytic and anticonvulsant properties. Since vitexin has been found in different medicinal plants popularly claimed as anxiolytics and/or anticonvulsants, this work has both ethnopharmacological and pharmaceutical relevance. This work may be useful for the development of new pharmacological probes not only for anxiety and epilepsy patients relieve in the future but also, and indirectly, for the better understanding of pathological events underlying both anxiety and epilepsy themselves.
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